ASML

1,176.6

-0.63%↓

SAP

149.3

-4.83%↓

IFX

37.76

-2.61%↓

NOKIA.FI

6.94

0%↓

STMPA.FR

26.58

-2.42%↓

ASML

1,176.6

-0.63%↓

SAP

149.3

-4.83%↓

IFX

37.76

-2.61%↓

NOKIA.FI

6.94

0%↓

STMPA.FR

26.58

-2.42%↓

ASML

1,176.6

-0.63%↓

SAP

149.3

-4.83%↓

IFX

37.76

-2.61%↓

NOKIA.FI

6.94

0%↓

STMPA.FR

26.58

-2.42%↓

ASML

1,176.6

-0.63%↓

SAP

149.3

-4.83%↓

IFX

37.76

-2.61%↓

NOKIA.FI

6.94

0%↓

STMPA.FR

26.58

-2.42%↓

ASML

1,176.6

-0.63%↓

SAP

149.3

-4.83%↓

IFX

37.76

-2.61%↓

NOKIA.FI

6.94

0%↓

STMPA.FR

26.58

-2.42%↓

Search

Societe BIC SA

Open

SectorTechnology

51.8 1.57

Overview

Share price change

24h

Current

Min

50.8

Max

52.1

Key metrics

By Trading Economics

Income

-66M

9.8M

Sales

-64M

1B

P/E

Sector Avg

12.813

77.27

Dividend yield

4.42

Profit margin

0.963

Employees

13,000

EBITDA

-190M

-17M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+0.39% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.42%

2.29%

Next Earnings

28 kwi 2026

Market Stats

By TradingEconomics

Market Cap

-142M

2.2B

Previous open

50.23

Previous close

51.8

News Sentiment

By Acuity

25%

75%

65 / 376 Ranking in Technology

Technical Score

By Trading Central

Confidence

Bearish Evidence

Societe BIC SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 mar 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar 2026, 22:55 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mar 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar 2026, 22:42 UTC

Market Talk
Major News Events

Global Equities Roundup: Market Talk

23 mar 2026, 22:42 UTC

Market Talk
Major News Events

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar 2026, 22:18 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mar 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar 2026, 21:10 UTC

Major News Events

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mar 2026, 20:50 UTC

Market Talk
Earnings
Major News Events

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Societe BIC SA Forecast

Price Target

By TipRanks

0.39% upside

12 Months Forecast

Average 52 EUR  0.39%

High 53 EUR

Low 51 EUR

Based on 2 Wall Street analysts offering 12 month price targets forSociete BIC SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

2 ratings

0

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

55.4 / 57.1Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

65 / 376 Ranking in Technology

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Societe BIC SA

Société BIC SA manufactures and sells stationery, lighter, shaver, and other products worldwide. It offers ball and coloring felt pens, glitter pens, markers, graphic and coloring pencils, shavers, mechanical pencils, sticky notes, printing products, stationery dyes, leads, white boards, correction tapes; pocket, utility, and decorated lighters; paints, gouache, watercolor, gels, highlighters, and various other products. The company also provides refillable shavers, permanent and temporary tattoo markers, semi permanent tattoo, and smart reusable notebooks, kits, crafting accessories, modeling clay and slime, refills, razor for men and women, and razor cartridges. In addition, it sells batteries and shaving preps; and advertising and promotional products. Further, the company is involved in the provision of delivery services; production of industrial equipment; manufacture and sale of blades; and manufacture and distribution of IT solutions and consumer products, as well as insurance activities. It markets its products primarily under the BIC, BIC Kids, Cello, Lucky, RocketBook, Tipp-Ex, BIC Wite-Out, Tattly, ami, DJEEP, InkBox, BIC Soleil, BIC Evolution, BodyMark, and other brands through a range of channels, including retail mass-market distributors, traditional stores, and office product suppliers, as well as an e-commerce site. The company was founded in 1944 and is headquartered in Clichy, France.
help-icon Live chat